Current Editions
Gilead seeks to defend HIV, reset I&I and bolster oncology
Patient-centric HIV interventions, oncology deals and an I&I rebuild are on the 2026 strategic agenda for Gilead
Product Development
Product Development
AL-S Pharma tests how far SOD1 biology extends into sporadic ALS
Phase II data suggest some sporadic ALS cases are SOD1-driven, but mixed all-comer results make patient stratification critical in Phase III
Deals
Gilead seeks to put Galapagos’ cash to work as it buys bispecifics developer Ouro
Deal in the works to add BCMA-targeting T cell engager to Belgian biotech’s thin pipeline, as its partner commits nearly $1.7B up front to buy NewCo
BioCentury ISSN 1097-7201